Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Protagonist Therapeutics Inc (NQ: PTGX )

17.52 +0.10 (+0.57%)
Streaming Delayed Price Updated: 2:46 PM EST, Nov 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 330,686
Open 17.37
Bid (Size) 17.51 (2)
Ask (Size) 17.52 (2)
Prev. Close 17.42
Today's Range 17.13 - 17.72
52wk Range 7.235 - 30.10
Shares Outstanding 57,678,122
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Protagonist Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-to-Head Comparisons with Deucravacitinib
Via ACCESSWIRE
Protagonist Therapeutics Reports Granting of Inducement Awards
Via ACCESSWIRE

Performance

YTD
+62.52%
+62.52%
1 Month
+22.69%
+22.69%
3 Month
-13.48%
-13.48%
6 Month
-31.21%
-31.21%
1 Year
+138.04%
+138.04%

More News

Read More
Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most On
Via The Motley Fool
Protagonist Therapeutics Ranked in the Top 3% of Fastest-Growing Companies in North America on the 2023 Deloitte Technology Fast 500(TM)
Via ACCESSWIRE
The Latest Analyst Ratings for Protagonist Therapeutics
Via Benzinga
Protagonist Therapeutics Announces Abstracts Selected for Oral and Poster Presentations at the American Society of Hematology 2023 Annual Meeting
Via ACCESSWIRE
Protagonist Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Protagonist Announces Advancement of JNJ-2113 Across Multiple Indications
Via ACCESSWIRE
What 6 Analyst Ratings Have To Say About Protagonist Therapeutics
Via Benzinga
Protagonist Announces Achievement of $50M Milestone Event After Third Patient is Dosed in Phase 3 Study of JNJ-2113 in Moderate-to-Severe Psoriasis
Via ACCESSWIRE
Protagonist Therapeutics to Participate in Upcoming Investor Conferences
Via ACCESSWIRE
Protagonist Therapeutics Announces Appointment of Daniel Swisher to Its Board of Directors
Via ACCESSWIRE
Protagonist Therapeutics Reports Granting of Inducement Award
Via ACCESSWIRE
Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty
Via FinancialNewsMedia
Protagonist Receives $34 Million from Warrant Exercises
Via ACCESSWIRE
Expert Ratings for Protagonist Therapeutics
Via Benzinga
Protagonist Therapeutics to Present at Upcoming Investor Conferences
Via ACCESSWIRE
Protagonist Therapeutics Reports Granting of Inducement Award
Via ACCESSWIRE
Protagonist Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Quarter
Via Benzinga
Protagonist Therapeutics Reports Granting of Inducement Award
Via ACCESSWIRE
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Analyst Boosts Protagonist Therapeutics Price Target, Says Psoriasis Data Impressive
Via Benzinga
Meta Platforms To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday
Via Benzinga
Protagonist Therapeutics-Janssen Partnered Psoriasis Candidate Fall Short Of Rival Treatment
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.